Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation

Summary

Carbon monoxide (CO) is a gaseous autacoid known to positively regulate vascular tone; however, its role in angiogenesis is unknown. The aim of this study was to investigate the effect of CO on angiogenesis and vascular endothelial growth factor (VEGF) receptor-2 phosphorylation. Human umbilical vein endothelial cells (HUVECs) were cultured on growth factor-reduced Matrigel and treated with a CO-releasing molecule (CORM-2) or exposed to CO gas (250 ppm). Here, we report the surprising finding that exposure to CO inhibits vascular endothelial growth factor (VEGF)-induced endothelial cell actin reorganisation, cell proliferation, migration and capillary-like tube formation. Similarly, CO suppressed VEGF-mediated phosphorylation of VEGFR-2 at tyrosine residue 1175 and 1214 and basic fibroblast growth factor- (FGF-2) and VEGF-mediated Akt phosphorylation. Consistent with these data, mice exposed to 250 ppm CO (1h/day for 14 days) exhibited a marked decrease in FGF-2-induced Matrigel plug angiogenesis (p<0.05). These data establish a new biological function for CO in angiogenesis and point to a potential therapeutic use for CO as an anti-angiogenic agent in tumour suppression.

Keywords

Carbon monoxide - vascular endothelial growth factor - angiogenesis - endothelial cells - vascular endothelial growth factor receptor-2

• References

• 1 Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularisation: NO for endothelial progenitor cells. Trends Mol Med 2004; 10: 143-145.
• 2 Dimmeler S, Fleming I, Fisslthaler B. et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.
• 3 Murohara T, Asahara T, Silver M. et al. Nitric oxide synthase modulates angio-genesis in response to tissue ischaemia. J Clin Invest 1998; 101: 2567-2578.
• 4 Ahmad S, Hewett PW, Wang P. et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 2006; 99: 715-722.
• 5 Dulak J, Deshane J, Jozkowicz A. et al. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008; 117: 231-241.
• 6 Christodoulides N, Durante W, Kroll MH. et al. Vascular smooth muscle cell heme oxygenases generate guanylyl cyclase-stimulatory carbon monoxide. Circulation 1995; 91: 2306-2309.
• 7 Kaide JI, Zhang F, Wei Y. et al. Carbon monoxide of vascular origin attenuates the sensitivity of renal arterial vessels to vasoconstrictors. J Clin Invest 2001; 107: 1163-1171.
• 8 Mansouri A, Perry CA. Alteration of platelet aggregation by cigarette smoke and carbon monoxide. Thromb Haemost 1982; 48: 286-288.
• 9 Yet SF, Layne MD, Liu X. et al. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J 2003; 17: 1759-1761.
• 10 Moulton KS, Vakili K, Zurakowski D. et al. Inhibition of plaque neovascularisation reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003; 100: 4736-4741.
• 11 Celletti FL, Hilfiker PR, Ghafouri P. et al. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001; 37: 2126-2130.
• 12 Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterisation of the enzyme. J Biol Chem 1969; 244: 6388-6394.
• 13 Otterbein LE, Kolls JK, Mantell LL. et al. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Invest 1999; 103: 1047-1054.
• 14 Bussolati B, Ahmed A, Pemberton H. et al. Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. Blood 2004; 103: 761-766.
• 15 Abraham NG, Scapagnini G, Kappas A. Human heme oxygenase: cell cycle-dependent expression and DNA microarray identification of multiple gene responses after transduction of endothelial cells. J Cell Biochem 2003; 90: 1098-1111.
• 16 Deramaudt BM, Braunstein S, Remy P. et al. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 1998; 68: 121-127.
• 17 Deshane J, Chen S, Caballero S. et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med 2007; 204: 605-618.
• 18 Li Volti G, Sacerdoti D, Sangras B. et al. Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells. Antioxid Redox Signal 2005; 07: 704-710.
• 19 Sato K, Balla J, Otterbein L. et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol 2001; 166: 4185-4194.
• 20 Otterbein LE, Bach FH, Alam J. et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000; 06: 422-428.
• 21 Wegiel B, Gallo D, Csizmadia E. et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumour growth. Cancer Res 2013; 73: 7009-7021.
• 22 Gueron G, De Siervi A, Ferrando M. et al. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res 2009; 07: 1745-1755.
• 23 Vitek L, Gbelcova H, Muchova L. et al. Antiproliferative effects of carbon mon-oxide on pancreatic cancer. Digest Liver Dis 2014; 46: 369-375.
• 24 Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nature Rev Drug Discov 2010; 09: 728-743.
• 25 Motterlini R, Clark JE, Foresti R. et al. Carbon monoxide-releasing molecules: characterisation of biochemical and vascular activities. Circ Res 2002; 90: E17-24.
• 26 Bussolati B, Dunk C, Grohman M. et al. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001; 159: 993-1008.
• 27 Sawle P, Foresti R, Mann BE. et al. Carbon monoxide-releasing molecules (CORMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. Br J Pharmacol 2005; 145: 800-810.
• 28 Cudmore M, Ahmad S, Al-Ani B. et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-1797.
• 29 Ahmad S, Cudmore MJ, Wang K. et al. Angiopoietin-1 induces migration of monocytes in a tie-2 and integrin-independent manner. Hypertension 2010; 56: 477-483.
• 30 Nehls V, Drenckhahn D. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 1995; 50: 311-322.
• 31 Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
• 32 Ross JF, Liu X, Dynlacht BD. Mechanism of transcriptional repression of E2F by the retinoblastoma tumour suppressor protein. Mol Cell 1999; 03: 195-205.
• 33 Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine & growth factor reviews 2005; 16: 139-149.
• 34 Olsson AK, Dimberg A, Kreuger J. et al. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 2006; 07: 359-371.
• 35 Kureishi Y, Luo Z, Shiojima I. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 06: 1004-1010.
• 36 Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650.
• 37 Rose CS, Jones RA, Jenkins Jr. LJ. et al. The acute hyperbaric toxicity of carbon monoxide. Toxicol Appl Pharmacol 1970; 17: 752-760.
• 38 Chekhonin VP, Shein SA, Korchagina AA. et al. VEGF in tumour progression and targeted therapy. Current cancer drug targets 2013; 13: 423-443.
• 39 Breier G, Albrecht U, Sterrer S. et al. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114: 521-532.
• 40 Togane Y, Morita T, Suematsu M. et al. Protective roles of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am J Physiol Heart Circ Physiol 2000; 278: H623-632.
• 41 Fischer C, Jonckx B, Mazzone M. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumours without affecting healthy vessels. Cell 2007; 131: 463-475.
• 42 Matsumoto T, Bohman S, Dixelius J. et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumour angiogenesis. EMBO J 2005; 24: 2342-2353.
• 43 Sakurai Y, Ohgimoto K, Kataoka Y. et al. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA 2005; 102: 1076-1081.
• 44 Takahashi T, Yamaguchi S, Chida K. et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20: 2768-2778.
• 45 Batzlsperger CA, Achatz S, Spreng J. et al. Evidence for a possible inhibitory interaction between the HO-1/CO- and Akt/NO-pathways in human endothelial cells. Cardiovasc Drugs Ther 2007; 21: 347-355.
• 46 Dulak J, Jozkowicz A, Foresti R. et al. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. Antioxid Redox Signal 2002; 04: 229-240.
• 47 Nanobashvili J, Jozkowicz A, Neumayer C. et al. Comparison of Angiogenic Potential of Human Microvascular Endothelial Cells and Human Umbilical Vein Endothelial Cells. Eur Surg 2003; 35: 214-219.
• 48 Page C, Rose M, Yacoub M. et al. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 141: 673-683.
• 49 Huk I. Comparison of angiogenic potential of human microvascular endothelial cells and human umbilical vein endothelial cells. Eur Surg Res 2003; 35: 214-218.